195 related articles for article (PubMed ID: 21737256)
1. Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients.
Ali AM; Ueno T; Tanaka S; Takada M; Ishiguro H; Abdellah AZ; Toi M
Eur J Cancer; 2011 Oct; 47(15):2265-72. PubMed ID: 21737256
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET).
Vasseur A; Cabel L; Tredan O; Chevrier M; Dubot C; Lorgis V; Jacot W; Goncalves A; Debled M; Levy C; Ferrero JM; Jouannaud C; Luporsi E; Mouret-Reynier MA; Dalenc F; Lemonnier J; Savignoni A; Tanguy ML; Bidard FC; Pierga JY
Angiogenesis; 2020 May; 23(2):193-202. PubMed ID: 31773439
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Pierga JY; Bidard FC; Autret A; Petit T; Andre F; Dalenc F; Levy C; Ferrero JM; Romieu G; Bonneterre J; Lerebours F; Bachelot T; Kerbrat P; Campone M; Eymard JC; Mouret-Reynier MA; Gligorov J; Hardy-Bessard AC; Lortholary A; Soulie P; Boher JM; Proudhon C; Charafe-Jaufret E; Lemonnier J; Bertucci F; Viens P
Ann Oncol; 2017 Jan; 28(1):103-109. PubMed ID: 28177480
[TBL] [Abstract][Full Text] [Related]
4. On the origin of (CD105+) circulating endothelial cells.
Strijbos MH; Verhoef C; Gratama JW; Sleijfer S
Thromb Haemost; 2009 Aug; 102(2):347-51. PubMed ID: 19652886
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic significance of circulating endothelial cells in advanced non-small cell lung cancer patients.
Yuan DM; Zhang Q; Lv YL; Ma XQ; Zhang Y; Liu HB; Song Y
Tumour Biol; 2015 Nov; 36(11):9031-7. PubMed ID: 26084612
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.
Bidard FC; Mathiot C; Degeorges A; Etienne-Grimaldi MC; Delva R; Pivot X; Veyret C; Bergougnoux L; de Cremoux P; Milano G; Pierga JY
Ann Oncol; 2010 Sep; 21(9):1765-1771. PubMed ID: 20233745
[TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].
Kulka J; Tokés AM; Tóth AI; Szász AM; Farkas A; Borka K; Járay B; Székely E; Istók R; Lotz G; Madaras L; Korompay A; Harsányi L; László Z; Rusz Z; Molnár BA; Molnár IA; Kenessey I; Szentmártoni G; Székely B; Dank M
Magy Onkol; 2009 Dec; 53(4):335-43. PubMed ID: 20071305
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
[TBL] [Abstract][Full Text] [Related]
9. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer.
Fürstenberger G; von Moos R; Lucas R; Thürlimann B; Senn HJ; Hamacher J; Boneberg EM
Br J Cancer; 2006 Feb; 94(4):524-31. PubMed ID: 16450002
[TBL] [Abstract][Full Text] [Related]
10. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
Matsusaka S; Suenaga M; Mishima Y; Takagi K; Terui Y; Mizunuma N; Hatake K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):763-8. PubMed ID: 21170650
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
12. Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination.
Dhakal HP; Naume B; Synnestvedt M; Borgen E; Kaaresen R; Schlichting E; Wiedswang G; Bassarova A; Giercksky KE; Nesland JM
Clin Cancer Res; 2008 Apr; 14(8):2341-50. PubMed ID: 18413823
[TBL] [Abstract][Full Text] [Related]
13. Characterization of CD45-/CD31+/CD105+ circulating cells in the peripheral blood of patients with gynecologic malignancies.
Yu HK; Lee HJ; Choi HN; Ahn JH; Choi JY; Song HS; Lee KH; Yoon Y; Yi LS; Kim JS; Kim SJ; Kim TJ
Clin Cancer Res; 2013 Oct; 19(19):5340-50. PubMed ID: 23922300
[TBL] [Abstract][Full Text] [Related]
14. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells.
Ueno T; Masuda N; Kamigaki S; Morimoto T; Akiyama F; Kurosumi M; Tsuda H; Mikami Y; Tanaka S; Morita S; Toi M
Cancer Med; 2018 Jun; 7(6):2442-2451. PubMed ID: 29733541
[TBL] [Abstract][Full Text] [Related]
16. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
Onstenk W; Kraan J; Mostert B; Timmermans MM; Charehbili A; Smit VT; Kroep JR; Nortier JW; van de Ven S; Heijns JB; Kessels LW; van Laarhoven HW; Bos MM; van de Velde CJ; Gratama JW; Sieuwerts AM; Martens JW; Foekens JA; Sleijfer S
Mol Cancer Ther; 2015 Mar; 14(3):821-7. PubMed ID: 25552367
[TBL] [Abstract][Full Text] [Related]
17. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
[TBL] [Abstract][Full Text] [Related]
18. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
Zhou B; Yang DQ; Xie F
Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of primary systemic chemotherapy regimen containing anthracyclines with/without taxanes in comparison to CMF in women with early breast cancer.
Gschwantler-Kaulich D; Fink-Retter A; Hudelist G; Bachrich T; Ledesma M; Ruecklinger E; Kubista E; Singer CF
J Chemother; 2007 Dec; 19(6):731-8. PubMed ID: 18230558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
